AlAzmi Aeshah, Alasmari Zahra, Yousef Consuela, Alenazi Ahmed, AlOtaibi Mohammed, AlSaedi Hani, AlShaikh Adnan, AlObathani Amani, Ahmed Omaima, Goronfolah Loie, Alahmari Mousa
Ministry of National Guard Health Affairs (MNGHA), King Abdulaziz Medical City (KAMC), Jeddah, Saudi Arabia.
Princes Noorah Oncology Center, Pediatric Oncology/Hematology/BMT Section, King Abdulaziz Medical City (KAMC), Jeddah, Saudi Arabia.
Hosp Pharm. 2021 Dec;56(6):690-696. doi: 10.1177/0018578720942226. Epub 2020 Aug 31.
Prescribing a drug for a child is not an easy task and requires using the best available evidence as a guide, especially when a drug is used off-label. The practice of prescribing a drug for off-label use is fairly widespread worldwide. The FDA does not regulate prescribing patterns or practices of individual practitioners and, therefore, allows off-label use. The main objective of this study is to evaluate off-label prescribing among the pediatric population in the Kingdom of Saudi Arabia (KSA).
This is a retrospective, simple random selection observational study of children (≤15 years) who visited pediatric clinics and had at least 1 drug prescribed over a 12-month period (January to December 2018).
A total of 865 drugs (mean 1 and SD 0.24) were prescribed to 326 children. Off-label was identified in 39.4% of the drugs with a frequency of 512 (as 1 drug may belong to more than 1 off-label category). The most common reason for off-label prescribing was related to doses that were "higher or lower than the recommended use" (48.6%), and the most frequently identified drug class prescribed for off-label use was anti-infective drugs for systemic use (39.9%). The percentage of off-label drug use was found to be higher in girls and in the age group of 1 month to 2 years ( = .001) for both variables. In addition, a significant association was found between off label drug use and the total number of drugs prescribed, < .001.
The findings of this study showed a high incidence of off-label prescribing mainly related to dosing and indication. The results of this observational study support the need to establish a unified national pediatric dosing formulary guide to ensure safe drug use in pediatrics.
给儿童开药并非易事,需要以现有最佳证据为指导,尤其是当药物用于超说明书用药时。超说明书用药的做法在全球范围内相当普遍。美国食品药品监督管理局(FDA)并不规范个体从业者的开药模式或行为,因此允许超说明书用药。本研究的主要目的是评估沙特阿拉伯王国(KSA)儿科人群中的超说明书用药情况。
这是一项回顾性、简单随机抽样的观察性研究,研究对象为就诊于儿科诊所且在12个月期间(2018年1月至12月)至少开具过1种药物的15岁及以下儿童。
共给326名儿童开具了865种药物(均值为1,标准差为0.24)。39.4%的药物存在超说明书用药情况,涉及512次(因为一种药物可能属于不止一种超说明书用药类别)。超说明书用药最常见的原因与“高于或低于推荐用量”的剂量有关(48.6%),超说明书使用最常见的药物类别是全身用抗感染药物(39.9%)。发现女孩以及1个月至2岁年龄组的超说明书用药比例在这两个变量上均更高(P = 0.001)。此外,超说明书用药与开具的药物总数之间存在显著关联(P < 0.001)。
本研究结果显示超说明书用药发生率较高,主要与剂量和适应证有关。这项观察性研究的结果支持建立统一的国家儿科用药剂量处方指南以确保儿科安全用药的必要性。